全文获取类型
收费全文 | 4199篇 |
免费 | 208篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 81篇 |
妇产科学 | 157篇 |
基础医学 | 500篇 |
口腔科学 | 30篇 |
临床医学 | 375篇 |
内科学 | 1218篇 |
皮肤病学 | 116篇 |
神经病学 | 343篇 |
特种医学 | 159篇 |
外科学 | 619篇 |
综合类 | 14篇 |
预防医学 | 130篇 |
眼科学 | 53篇 |
药学 | 292篇 |
中国医学 | 2篇 |
肿瘤学 | 319篇 |
出版年
2023年 | 17篇 |
2022年 | 40篇 |
2021年 | 92篇 |
2020年 | 55篇 |
2019年 | 60篇 |
2018年 | 99篇 |
2017年 | 59篇 |
2016年 | 83篇 |
2015年 | 90篇 |
2014年 | 123篇 |
2013年 | 172篇 |
2012年 | 251篇 |
2011年 | 281篇 |
2010年 | 162篇 |
2009年 | 135篇 |
2008年 | 248篇 |
2007年 | 244篇 |
2006年 | 258篇 |
2005年 | 212篇 |
2004年 | 192篇 |
2003年 | 219篇 |
2002年 | 202篇 |
2001年 | 115篇 |
2000年 | 114篇 |
1999年 | 85篇 |
1998年 | 46篇 |
1997年 | 31篇 |
1996年 | 37篇 |
1995年 | 32篇 |
1994年 | 34篇 |
1993年 | 23篇 |
1992年 | 78篇 |
1991年 | 63篇 |
1990年 | 46篇 |
1989年 | 53篇 |
1988年 | 58篇 |
1987年 | 50篇 |
1986年 | 37篇 |
1985年 | 45篇 |
1984年 | 20篇 |
1983年 | 18篇 |
1982年 | 16篇 |
1981年 | 20篇 |
1980年 | 15篇 |
1979年 | 18篇 |
1978年 | 9篇 |
1976年 | 12篇 |
1974年 | 9篇 |
1973年 | 9篇 |
1966年 | 7篇 |
排序方式: 共有4431条查询结果,搜索用时 312 毫秒
1.
2.
Carmine Nieuwstraten N Renee Labiris Anne Holbrook 《Revue canadienne de psychiatrie》2006,51(5):300-316
OBJECTIVE: Antidepressants are commonly used drugs with potential for numerous drug interactions. This study aims to systematically review the literature on drug interactions with antidepressants. METHODS: We searched MEDLINE (1966 to November 2003) and EMBASE (1980 to 2003), using the heading drug interactions combined with individual antidepressant names. We restricted searches to English-language articles and human studies. We screened drug interaction texts and review articles for relevant studies. We included articles reporting original human data on drug interactions with antidepressants commonly used in North America. Articles were independently evaluated by 2 reviewers on clinical effect, clinical significance, and quality of evidence. Discrepancies were resolved by consensus. RESULTS: There were 904 eligible interactions, involving 9509 patients, for a total of 598 summary interactions. Of these, 439 (73%) demonstrated an interaction, 148 (25%) had no effect, and 11 (2%) had conflicting evidence. For 510 interactions (85%), the quality of evidence was poor. It was fair for 67 (11%) interactions and good for 10 (2%) interactions. There were no interactions with excellent quality of evidence. There were 145 (24%) interactions of major clinical significance. These were predominantly hypertensive emergencies and serotonin syndrome. Most interacting drugs had central nervous system (CNS) activity. As expected, monoamine oxidase inhibitors (MAOIs) appear to be the most problematic family in terms of potential for serious drug interactions. CONCLUSIONS: Drug interactions with antidepressants are an important cause for concern, but this concern is based primarily on poor evidence. We recommend caution when combining antidepressants with other CNS drugs, particularly when coadministering MAOIs with other substances. 相似文献
3.
Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects 总被引:2,自引:0,他引:2
F Galletti M L Fasano L A Ferrara A Groppi M Montagna M Mancini 《Journal of clinical pharmacology》1989,29(3):212-216
Beta-blockers are among the most widely used antihypertensive drugs. They differ from each other in regard to several factors such as: beta-agonist activity, beta 1-selectivity and solubility. Aim of this work was to evaluate the influence of obesity on the kinetics and the antihypertensive effect of two Beta-blockers with different solubility such as: the water-soluble, atenolol and the liposoluble, metoprolol. The study was carried out according to an open randomized cross-over design. Eight obese hypertensive patients, after a two week washout period, were randomly allocated to a four week treatment. After a two week intermediate washout period, each patient switched to the other treatment for an additional four week period. On the first and the last day of each treatment the subjects were hospitalized to collect blood samples for the assay of the two drugs and to measure cardiovascular parameters. Obesity does not exert any effect on the kinetics of the water-soluble beta-blocker, atenolol, while markedly interferes with that of the liposoluble, without any apparent influence on its anti-hypertensive effect. These findings extend to obese hypertensives the concept that the plasma concentrations of beta-blocking agents are not reliable predictors of their therapeutic effect. 相似文献
4.
5.
B E Ferrara 《Southern medical journal》1991,84(12):1487-1492
6.
7.
Carmine Zoccali Renke Maas Sebastiano Cutrupi Patrizia Pizzini Piero Finocchiaro Francesco Cambareri Vincenzo Panuccio Carmela Martorano Friedrich Schulze Giuseppe Enia Giovanni Tripepi Rainer Boger 《Nephrology, dialysis, transplantation》2007,22(3):801-806
BACKGROUND AND METHODS: The endogenous inhibitor of nitric oxide synthase (NOs) asymmetrical dimethyl-arginine (ADMA) has been implicated as a possible modulator of inducible NOs during acute inflammation. We examined the evolution in the plasma concentration of ADMA measured at the clinical outset of acute inflammation and after its resolution in a series of 17 patients with acute bacterial infections. RESULTS: During the acute phase of inflammation/infection, patients displayed very high levels of C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin and nitrotyrosine. Simultaneous plasma ADMA concentration was similar to that in healthy subjects while symmetric dimethyl-arginine (SDMA) levels were substantially increased and directly related with creatinine. When infection resolved, ADMA rose from 0.62 +/- 0.23 to 0.80 +/- 0.18 micromol/l (+29%, P = 0.01) while SDMA remained unmodified. ADMA changes were independent on concomitant risk factor changes and inversely related with baseline systolic and diastolic pressure. Changes in the ADMA/SDMA ratio were compatible with the hypothesis that inflammatory cytokines activate ADMA degradation. CONCLUSIONS: Resolution of acute inflammation is characterized by an increase in the plasma concentration of ADMA. The results imply that ADMA suppression may actually serve to stimulate NO synthesis or that in this situation plasma ADMA levels may not reflect the inhibitory potential of this methylarginine at the cellular level. 相似文献
8.
Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. 总被引:1,自引:0,他引:1
Francesco Locatelli Simeone Andrulli Bruno Memoli Camilla Maffei Lucia Del Vecchio Stefano Aterini Walter De Simone Antonella Mandalari Giuliano Brunori Marcello Amato Bruno Cianciaruso Carmine Zoccali 《Nephrology, dialysis, transplantation》2006,21(4):991-998
BACKGROUND: Chronic kidney disease patients who are resistant to erythropoietin (EPO) treatment may suffer from malnutrition and/or inflammation. METHODS: In a cross-sectional study of haemodialysis patients, we investigated the relationship between the natural logarithm of the weekly EPO dose normalized for post-dialysis body weight and outcome measures of nutrition and/or inflammation [BMI, albumin and C reactive protein (CRP)] by means of multiple linear regression analysis. On the basis of the decile distribution of weekly EPO doses, we also evaluated four groups of patients: untreated, hyper-responders, normo-responders and hypo-responders. RESULTS: Six hundred and seventy-seven adult haemodialysis patients were recruited from five Italian centres. BMI and albumin were lower in the hypo-responders than in the other groups (21.3+/-3.8 vs 24.4+/-4.7 kg/m(2), P<0.001; and 3.8+/-0.6 vs 4.1+/-0.4 g/dl, P<0.001), whereas the median CRP level was higher (1.9 vs 0.8 mg/dl, P = 0.004). The median weekly EPO dose ranged from 30 IU/kg/week in the hyper-responsive group to 263 IU/kg/week in the hypo-responsive group. Transferrin saturation linearly decreased from the hyper- to hypo-responsive group (37+/-15 to 25+/-10%, P = 0.003), without any differences in transferrin levels. Ferritin levels were lower in the hypo-responsive than in the other patients (median 318 vs 445 ng/ml, P = 0.01). At multiple linear regression analysis, haemoglobin, BMI, albumin, CRP and serum iron levels were independently associated with the natural logarithm of the weekly EPO dose (R(2) = 0.22). CONCLUSIONS: Our findings support a clear association between EPO responsiveness and nutritional and inflammation variables in haemodialysis patients; iron deficiency is still a major cause of hypo-responsiveness. 相似文献
9.
10.
F Scaglione F Ferrara S Dugnani M Falchi G Santoro F Fraschini 《Drugs under experimental and clinical research》1990,16(10):537-542
The effect of Panax ginseng extracts on cell-mediated immune functions in man has been investigated. Three groups, each consisting of twenty healthy volunteers, were treated under conditions of double blindness with capsules containing lactose (Control Group B), with capsules containing 100 mg of aqueous extract of the drug (Group A), and with capsules containing 100 mg of standardized extract of the drug (Group C). All the patients took one capsule every 12 h for 8 weeks. Blood samples were withdrawn before beginning the treatment, at the fourth week and at the eighth week. The immune parameters examined were the following: chemotaxis of PMNs, phagocytosis index (PHI), phagocytosis fraction (PHF), intracellular killing, total lymphocytes (T3), T helper (T4) subset, suppressor cells (T8) subset, blastogenesis of circulating lymphocytes, natural killer-cell activity (NK). Chemotaxis proved to be enhanced (p less than 0.05) already at the fourth week in Group A as well as in Group C; the increase became even more marked (p less than 0.001) at the eight week in subjects belonging to Group C. PHI and PHF proved to be enhanced (p less than 0.05) at the eighth week in subjects of Group A; these increases were found to be higher in subjects of Group C (p less than 0.001) already starting at the fourth week. Intracellular killing was shown to be significantly increased (p less than 0.05) already at the fourth week in Groups A and C; the increase becomes highly significant in both groups (p less than 0.001) at the eighth week; however, a significant increase (p less than 0.05) at the eighth week was also noticed in the placebo group (Group B).(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献